Summary
GlobalData has released its pharma report, “Major Depressive Disorder - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing MDD Market. The report identifies and analyses the key companies shaping and driving the global MDD market. The report provides insight into the competitive MDD landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.
Scope
- Investigation of current and future market competition for MDD
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of MDD sector through market impact analysis, future market scenario and company analysis
Reasons to buy
- Gain a high level view of the trends shaping and driving MDD market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global MDD market landscape? Identify, understand and capitalize
Companies Mentioned
Allergan
e-Therapeutics
Alkermes
Pfizer
Otsuka
Janssen
Eli Lilly
Lundbeck
Takeda
Axsome Therapeutics
'
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Introduction 7
2.1 Related Reports 7
2.2 Upcoming Related Reports 8
3 Market Outlook 9
3.1 Global Markets 9
3.1.1 Forecast 9
3.1.2 Drivers and Barriers - Global Issues 16
4 Current and Future Players 17
4.1 Overview 17
4.2 Trends in Corporate Strategy 19
4.3 Company Profiles 20
4.3.1 Allergan 20
4.3.2 e-Therapeutics 23
4.3.3 Alkermes 25
4.3.4 Pfizer 27
4.3.5 Otsuka 29
4.3.6 Janssen 32
4.3.7 Eli Lilly 35
4.3.8 Lundbeck 37
4.3.9 Takeda 40
4.3.10 Axsome Therapeutics 42
5 Appendix 44
5.1 Bibliography 44
5.2 Abbreviations 90
5.3 Methodology 101
5.4 Forecasting Methodology 101
5.4.1 Diagnosed NSCLC Patients 101
5.4.2 Percent Drug-Treated Patients 102
5.4.3 Drugs Included in Each Therapeutic Class 102
5.4.4 Launch and Patent Expiry Dates 105
5.4.5 General Pricing Assumptions 107
5.4.6 Individual Drug Assumptions 109
5.4.7 Generic Erosion 123
5.4.8 Pricing of Pipeline Agents 123
5.5 Primary Research - KOLs 128
5.5.1 KOLs 128
5.6 About the Authors 132
5.6.1 Analyst 132
5.6.2 Therapy Area Director 132
5.6.3 Epidemiologist 133
5.6.4 Global Head of Healthcare 133
5.7 About GlobalData 135
5.8 Disclaimer 135
1.1 List of Tables
Table 1: MDD Market - Drivers and Barriers, 2015-2025 16
Table 2: Key Companies in the MDD Market in the 7MM 18
Table 3: Allergan’s MDD Portfolio Assessment, 2016 22
Table 4: Allergan SWOT Analysis in MDD, 2015-2025 23
Table 5: e-Therapeutics’ MDD Portfolio Assessment, 2016 24
Table 6: e-Therapeutics SWOT Analysis in MDD, 2015-2025 25
Table 7: Alkermes’ MDD Portfolio Assessment, 2016 27
Table 8: Alkermes SWOT Analysis in MDD, 2015-2025 27
Table 9: Pfizer’s MDD Portfolio Assessment, 2016 28
Table 10: Pfizer SWOT Analysis in MDD, 2015-2025 29
Table 11: Otsuka’s MDD Portfolio Assessment, 2016 31
Table 12: Otsuka SWOT Analysis in MDD, 2015-2025 32
Table 13: Janssen’s MDD Portfolio Assessment, 2016 34
Table 14: Janssen SWOT Analysis in MDD, 2015-2025 35
Table 15: Eli Lilly’s MDD Portfolio Assessment, 2016 36
Table 16: Eli Lilly SWOT Analysis in MDD, 2015-2025 37
Table 17: Lundbeck’s MDD Portfolio Assessment, 2016 39
Table 18: Lundbeck SWOT Analysis in MDD, 2015-2025 40
Table 19: Takeda’s MDD Portfolio Assessment, 2016 41
Table 20: Takeda SWOT Analysis in MDD, 2015-2025 41
Table 21: Axsome Therapeutics’ MDD Portfolio Assessment, 2016 43
Table 22: Axsome Therapeutics SWOT Analysis in MDD, 2015-2025 43
Table 23: Key Launch Dates - Part I 105
Table 24: Key Launch Dates - Part II 106
Table 25: Key Patent Expiries 107
Table 26 Average Body Weight and Surface Area Across the 8MM 108
Table 27: Average Cost of Therapy of Alimta in the 8MM 110
Table 28: Average Cost of Therapy of Alecensa in the 8MM 111
Table 29: Average Cost of Therapy of Avastin 112
Table 30: Average Cost of Therapy of Cyramza 112
Table 31: Average Cost of Therapy of Gilotrif 113
Table 32: Average Cost of Therapy of Iressa 114
Table 33: Average Cost of Therapy of Portrazza 115
Table 34: Average Cost of Therapy of Tagrisso 116
Table 35: Average Cost of Therapy of Tarceva 117
Table 36: Average Cost of Therapy of Vargatef 117
Table 37: Average Cost of Therapy of Xalkori 118
Table 38: Average Cost of Therapy of Zykadia 119
Table 39: Average Cost of Therapy of Keytruda 120
Table 40: Average Cost of Therapy of Opdivo 121
Table 41: Average Cost of Therapy of Tecentriq 122
Table 42: Average Cost of Therapy of Conmana 123
Table 43: High-Prescribing Physicians Surveyed by Country 131
1.2 List of Figures
Figure 1: Global Sales by Region for MDD Therapies, 2015 and 2025 12
Figure 2: Global Sales by Region for MDD Therapies, 2015-2025 13
Figure 3: Global Sales by Drug Class for MDD Therapies, 2015 and 2025 14
Figure 4: Global Sales by Drug Class for MDD Therapies, 2015-2025 15
Figure 5: Company Portfolio Gap Analysis in MDD, 2015-2025 19
